Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero

Showing results (61-70 of 179) with videos related to

Pageof 18
Sort By:
Ecancermedicalscience|March 4, 2026
Short and long term central peripherally inserted catheters in hematological malignancy patients: clinical outcomes and safety. Single centre experienceCarlos Gómez Calcetero, Juanita Granados Diaz, Adriana Aya Porto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2011
A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignanciesMichelle A Fanale, Andres Forero-Torres, Joseph D Rosenblatt, et al.
Clinical Breast Cancer|July 9, 2013
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancerAndrew D Seidman, Alison K Conlin, Ariadne Bach, et al.
Oncotarget|May 26, 2016
Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patientsGladys Morrison, Divya Lenkala, Bonnie LaCroix, et al.
The Oncologist|August 19, 2018
Impact of Guideline-Discordant Treatment on Cost and Health Care Utilization in Older Adults with Early-Stage Breast CancerCourtney P Williams, Kelly M Kenzik, Andres Azuero, et al.
British Journal of Haematology|May 27, 2009
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphomaAndres Forero-Torres, John P Leonard, Anas Younes, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 24, 2005
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion proteinAndres Forero-Torres, Sui Shen, Hazel Breitz, et al.
Seminars in Oncology|April 2, 2013
A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancerBudhi S Yadav, Anshuma Bansal, Suresh C Sharma, et al.
Blood|December 15, 2007
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignanciesNancy L Bartlett, Anas Younes, Matthew H Carabasi, et al.
Blood|October 18, 2017
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HLJonathan W Friedberg, Andres Forero-Torres, Rodolfo E Bordoni, et al.
Pageof 18

Showing results (61-70 of 179) with videos related to

Sort By:
Pageof 18
Ecancermedicalscience|March 4, 2026
Short and long term central peripherally inserted catheters in hematological malignancy patients: clinical outcomes and safety. Single centre experienceCarlos Gómez Calcetero, Juanita Granados Diaz, Adriana Aya Porto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2011
A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignanciesMichelle A Fanale, Andres Forero-Torres, Joseph D Rosenblatt, et al.
Clinical Breast Cancer|July 9, 2013
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancerAndrew D Seidman, Alison K Conlin, Ariadne Bach, et al.
Oncotarget|May 26, 2016
Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patientsGladys Morrison, Divya Lenkala, Bonnie LaCroix, et al.
The Oncologist|August 19, 2018
Impact of Guideline-Discordant Treatment on Cost and Health Care Utilization in Older Adults with Early-Stage Breast CancerCourtney P Williams, Kelly M Kenzik, Andres Azuero, et al.
British Journal of Haematology|May 27, 2009
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphomaAndres Forero-Torres, John P Leonard, Anas Younes, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 24, 2005
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion proteinAndres Forero-Torres, Sui Shen, Hazel Breitz, et al.
Seminars in Oncology|April 2, 2013
A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancerBudhi S Yadav, Anshuma Bansal, Suresh C Sharma, et al.
Blood|December 15, 2007
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignanciesNancy L Bartlett, Anas Younes, Matthew H Carabasi, et al.
Blood|October 18, 2017
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HLJonathan W Friedberg, Andres Forero-Torres, Rodolfo E Bordoni, et al.
Pageof 18